Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer

被引：12

作者：

Fukahori, Masaru ^{[1
,2
]}

Okabe, Yoshinobu ^{[1
]}

Shimokawa, Mototsugu ^{[3
,4
]}

Otsuka, Taiga ^{[5
,6
]}

Koga, Futa ^{[7
]}

Ueda, Yujiro ^{[8
]}

Nakazawa, Junichi ^{[9
]}

Komori, Azusa ^{[10
]}

Otsu, Satoshi ^{[10
]}

Arima, Shiho ^{[11
]}

Makiyama, Akitaka ^{[12
,13
]}

Taguchi, Hiroki ^{[14
,15
]}

Honda, Takuya ^{[16
]}

Ushijima, Tomoyuki ^{[1
]}

Miwa, Keisuke ^{[17
]}

Shibuki, Taro ^{[18
,19
]}

Nio, Kenta ^{[20
,21
]}

Ide, Yasushi ^{[22
]}

Ureshino, Norio ^{[5
,23
]}

Mizuta, Toshihiko ^{[18
,24
]}

Mitsugi, Kenji ^{[20
,21
]}

Shirakawa, Tsuyoshi ^{[25
,26
]}

机构：

[1] Kurume Univ, Sch Med, Dept Med, Div Gastroenterol, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan

[2] Kyoto Univ Hosp, Kyoto Innovat Ctr Next Generat Clin Trials & iPS, 54 Kawaharacho, Sakyo Ku, Kyoto 6068507, Japan

[3] Natl Kyushu Canc Ctr, Clin Res Inst, 3-1-1 Notame,Minami Ku, Fukuoka, Fukuoka 8111395, Japan

[4] Yamaguchi Univ, Dept Biostat, Grad Sch Med, 1-1-1 Minamikogushi, Ube, Yamaguchi 7558505, Japan

[5] Saga Med Ctr Koseikan, Dept Med Oncol, Kasemachi, 400 Kase Machi, Saga, Saga 8408571, Japan

[6] Minato Med Clin, Dept Internal Med, 3-11-3 Nagahama,Chuo Ku, Fukuoka, Fukuoka 8100072, Japan

[7] Saga Med Ctr Koseikan, Dept Hepatobiliary & Pancreatol, 400 Kase Machi, Saga, Saga 8408571, Japan

[8] Japanese Red Cross Kumamoto Hosp, Dept Hematol & Oncol, 2-1-1 Nagamine-Minami,Higashi Ku, Kumamoto, Kumamoto 8618520, Japan

[9] Kagoshima City Hosp, Dept Med Oncol, 37-1 Uearata Cho, Kagoshima, Kagoshima 8908760, Japan

[10] Oita Univ, Fac Med, Dept Med Oncol & Hematol, 1-1 Idaigaoka,Hasama Machi, Yufu, Oita 8795593, Japan

[11] Kagoshima Univ, Grad Sch Med & Dent Sci, Digest & Lifestyle Dis, 8-35-1 Sakuragaoka, Kagoshima, Kagoshima 8908520, Japan

[12] Japan Community Healthcare Org Kyushu Hosp, Dept Hematol Oncol, Yahatanishi Ku, 1-8-1 Kishinoura,Yahatanishi Ku, Kitakyushu, Fukuoka 8068501, Japan

[13] Gifu Univ Hosp, Canc Ctr, 1-1 Yanagido, Gifu, Gifu 5011194, Japan

[14] Saiseikai Sendai Hosp, Dept Gastroenterol, 2-46 Harada Cho, Satsumasendai, Kagoshima 8950074, Japan

[15] Imamura Gen Hosp, Dept Gastroenterol, 11-23 Kamoike Shinmachi, Kagoshima, Kagoshima 8900064, Japan

[16] Nagasaki Univ, Grad Sch Biomed Sci, Dept Gastroenterol & Hepatol, 1-7-1 Sakamoto, Nagasaki, Nagasaki 8528501, Japan

[17] Kurume Univ Hosp, Multidisciplinary Treatment Canc Ctr, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan

[18] Imari Arita Kyoritsu Hosp, Dept Internal Med, 860 Ninose Ko,Arita Cho, Saga 8494193, Japan

[19] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan

[20] Sasebo Kyosai Hosp, Dept Med Oncol, 10-17 Shimanji Cho, Sasebo, Nagasaki 8578575, Japan

[21] Hamanomachi Hosp, Dept Med Oncol, 3-3-1 Nagahama,Chuo Ku, Fukuoka, Fukuoka 8108539, Japan

[22] Karatsu Red Cross Hosp, Dept Internal Med, 2430 Watada, Karatsu, Saga 8478588, Japan

[23] Kimitsu Chuo Hosp, Dept Med Oncol, 1010 Sakurai, Kisarazu, Chiba 2928535, Japan

[24] Fujikawa Hosp, Dept Internal Med, 1-2-6 Matsubara, Saga, Saga 8400831, Japan

[25] Fukuoka Wajiro Hosp, Dept Med Oncol, 2-2-75 Wajirogaoka,Higashi Ku, Fukuoka, Fukuoka 8110213, Japan

[26] Karatsu Higashi Matsuura Med Assoc Ctr, Dept Internal Med, 2566-11 Chiyoda Machi, Karatsu, Saga 8470041, Japan

来源：

SCIENTIFIC REPORTS | 2023年 / 13卷 / 01期

关键词：

FOLINIC ACID; SURVIVAL; OXALIPLATIN; THERAPY; JAPAN;

D O I：

10.1038/s41598-023-46924-0

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

First-line chemotherapy for patients with metastatic pancreatic cancer (MPC) includes gemcitabine plus nab-paclitaxel (GnP) and FOLFIRINOX (FFX). However, the efficacy of second-line chemotherapy and the role of combination chemotherapy in clinical practice is still unknown. Data was gathered from 14 hospitals in the Kyushu area of Japan from December 2013 to March 2017. The median overall survival (mOS) from second-line treatment was contrasted between patients who received second-line chemotherapy (CT group) and those who received the best supportive care (BSC group). Furthermore, the mOS of combination chemotherapy was compared to mono chemotherapy in the CT group. To control possible bias in the selection of treatment, we performed a propensity score-adjusted analysis. A total of 255 patients received GnP or FFX as first-line chemotherapy. There were 156 in the CT group and 77 in the BSC group of these. The CT group had a significantly longer mOS than the BSC group (5.2 vs. 2.6 months; adjusted hazard ratio (HR) 0.38; 95% CI 0.27-0.54). In the CT group, 89 patients received combination chemotherapy while 67 received mono chemotherapy. The mOS did not differ significantly between the combination and mono chemotherapy groups (5.5 vs. 4.8 months; adjusted HR 0.88; 95% CI 0.58-1.33). Among patients with MPC receiving second-line treatment, the CT group had a significantly longer mOS than the BSC group, but combination chemotherapy conferred no improvement in survival compared to mono chemotherapy.

引用

页数：10

共 18 条

[1]

Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]

[2] Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].

Burris, HA ;

Moore, MJ ;

Andersen, J ;

Green, MR ;

Rothenberg, ML ;

Madiano, MR ;

Cripps, MC ;

Portenoy, RK ;

Storniolo, AM ;

Tarassoff, P ;

Nelson, R ;

Dorr, FA ;

Stephens, CD ;

VanHoff, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413

[3] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [J].

Conroy, Thierry ;

Desseigne, Francoise ;

Ychou, Marc ;

Bouche, Olivier ;

Guimbaud, Rosine ;

Becouarn, Yves ;

Adenis, Antoine ;

Raoul, Jean-Luc ;

Gourgou-Bourgade, Sophie ;

de la Fouchardiere, Christelle ;

Bennouna, Jaafar ;

Bachet, Jean-Baptiste ;

Khemissa-Akouz, Faiza ;

Pere-Verge, Denis ;

Delbaldo, Catherine ;

Assenat, Eric ;

Chauffert, Bruno ;

Michel, Pierre ;

Montoto-Grillot, Christine ;

Ducreux, Michel .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1817-1825

[4] PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy [J].

Gill, Sharlene ;

Ko, Yoo-Joung ;

Cripps, Christine ;

Beaudoin, Annie ;

Dhesy-Thind, Sukhbinder ;

Zulfiqar, Muhammad ;

Zalewski, Pawel ;

Do, Thuan ;

Cano, Pablo ;

Lam, Wendy Yin Han ;

Dowden, Scot ;

Grassin, Helene ;

Stewart, John ;

Moore, Malcolm .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (32) :3914-+

[5] nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial [J].

Goldstein, David ;

El-Maraghi, Robert Hassan ;

Hammel, Pascal ;

Heinemann, Volker ;

Kunzmann, Volker ;

Sastre, Javier ;

Scheithauer, Werner ;

Siena, Salvatore ;

Tabernero, Josep ;

Teixeira, Luis ;

Tortora, Giampaolo ;

Van Laethem, Jean-Luc ;

Young, Rosemary ;

Penenberg, Darryl Neil ;

Lu, Brian ;

Romano, Alfredo ;

Von Hoff, Daniel D. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (02)

[6] Hypoxia and anemia: Factors in decreased sensitivity to radiation therapy and chemotherapy? [J].

Harrison, L ;

Blackwell, K .

ONCOLOGIST, 2004, 9 :31-40

[7] Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project [J].

Hori, Megumi ;

Matsuda, Tomohiro ;

Shibata, Akiko ;

Katanoda, Kota ;

Sobue, Tomotaka ;

Nishimoto, Hiroshi .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (09) :884-891

[8] Population-based Survival of Cancer Patients Diagnosed Between 1993 and 1999 in Japan: A Chronological and International Comparative Study [J].

Matsuda, Tomohiro ;

Ajiki, Wakiko ;

Marugame, Tomomi ;

Ioka, Akiko ;

Tsukuma, Hideaki ;

Sobue, Tomotaka .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (01) :40-51

[9] Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group [J].

Moore, Malcolm J. ;

Goldstein, David ;

Hamm, John ;

Figer, Arie ;

Hecht, Joel R. ;

Gallinger, Steven ;

Au, Heather J. ;

Murawa, Pawel ;

Walde, David ;

Wolff, Robert A. ;

Campos, Daniel ;

Lim, Robert ;

Ding, Keyue ;

Clark, Gary ;

Voskoglou-Nomikos, Theodora ;

Ptasynski, Mieke ;

Parulekar, Wendy .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) :1960-1966

[10] Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial [J].

Oettle, Helmut ;

Riess, Hanno ;

Stieler, Jens M. ;

Heil, Gerhard ;

Schwaner, Ingo ;

Seraphin, Joerg ;

Goerner, Martin ;

Moelle, Matthias ;

Greten, Tim F. ;

Lakner, Volker ;

Bischoff, Sven ;

Sinn, Marianne ;

Doerken, Bernd ;

Pelzer, Uwe .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (23) :2423-U209

← 1 2 →